Maria Diaz-puente, MD

Articles by Maria Diaz-puente, MD

Cisplatin/Paclitaxel vs Cisplatin/Teniposide for Advanced Non-Small-Cell Lung Cancer

ByGiuseppe Giaccone, MD, PhD,Pieter E. Postmus, MD, PhD,Ted A. W. Splinter, MD,Maria Diaz-puente, MD,Nico Van Zandwijk, MD, PhD,Giorgio V. Scagliotti, MD, PhD,Andrea Ardizzoni, MD,Jan Van Meerbeeck, MD,Channa Debruyne, MD,Tarek Sahmoud, MD

April 1st 1997

A total of 332 patients with advanced non-small-cell lung cancer were randomized by the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative

Latest Updated Articles

Cisplatin/Paclitaxel vs Cisplatin/Teniposide for Advanced Non-Small-Cell Lung Cancer
Published: April 1st 1997 | Updated:

Maria Diaz-puente, MD

Articles by Maria Diaz-puente, MD

Cisplatin/Paclitaxel vs Cisplatin/Teniposide for Advanced Non-Small-Cell Lung Cancer

Latest Updated Articles

Trending on CancerNetwork

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

FDA Approves Revumenib in R/R NPM1-Mutant AML

FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

Addressing Systemic Barriers to Dermatologic Consultation in Oncology Care